AI and Longevity: Reprogramming Human Time

Dear Readers,

We used to talk about longevity like it was a moonshot—a future promise buried under hype and glossy investor decks. But step back and the picture has changed: AI now writes protein maps, edits genomes, and flags the first whispers of disease in blood data and wearables. It’s not science fiction anymore; it’s engineering. The question has shifted from if we can extend healthy life to how responsibly we do it - and who gets access when health itself becomes a software problem.

In today’s issue, we track how AI is folding the biology of aging into code, from CRISPR precision to generative protein design—and what that means for the next decade of medicine. We’ll cut through the supplement noise, decode the “hallmarks of aging,” and show where progress is real versus wishful thinking. If you’ve ever wondered when the tech world’s promises start showing up in the lab (and your own body), this one’s for you.

All the best,

Longevity has moved from a Silicon Valley mood board to the clinic. In December 2023, the U.S. FDA approved the first CRISPR-based therapy (Casgevy) for sickle cell disease -proof that programmable biology can cross from papers to patients. In 2024, AlphaFold 3 landed, predicting the structures of proteins and their interactions with ligands, nucleic acids, and ions—turning once-muddled molecular “whispers” into increasingly legible blueprints for drug design. Together these milestones reframed a simple question: can we convert advances in AI and genome engineering into added healthy years this decade, not just prettier demos?